IE 11 est un très ancien navigateur et n’est pas supporté sur ce site.

5. Business combinations

In the first half of 2023, the scope of consolidation has changed as a result of the following transactions:

Acquisition of Padma AG. On 30 January 2023, Galenica acquired 100% of the shares in the Swiss company Padma AG. Padma AG is the parent company of the Padma Group with its two operating companies Padma Europe GmbH (Austria based) and Padma Deutschland GmbH (Germany based). Padma specialises in the manufacture and distribution of herbal formulations derived from Tibetan medicine.

The total purchase considerations amounted to CHF 23.3 million, of which CHF 20.9 million was settled in cash. A contingent consideration in the amount of CHF 2.4 million was recognised, which is due in 2026 if certain financial and operational targets are achieved. The fair value of the net identifiable asset amounted to CHF 14.2 million at the acquisition date. The goodwill of CHF 9.1 million was allocated to the operating segment Products & Care and corresponds to added value based on the acquirer-specific synergies expected to arise from the acquisition in expanding its complementary medicine portfolio and expanding its range of reimbursable medicines and the know-how of the employees gained. Transaction costs were not material. 

Acquisition of pharmacies. Galenica acquired 100% of the interests in pharmacies in various locations in Switzerland. Upon acquisition, the pharmacies were merged with Galenicare Ltd.

The total purchase consideration amounted to CHF 9.7 million, of which CHF 9.1 million was settled in cash. A deferred consideration in the amount of CHF 0.6 million was recognised, which is due in the second half year of 2023.  The fair value of the provisional net assets amounts to CHF 0.8 million at the acquisition date. The goodwill of CHF 8.9 million was allocated to the operating segment Products & Care and corresponds to the added value of the pharmacies based on their locations. Transaction costs were not material.

Business combinations

in thousand CHF

Padma

Pharmacies

Total

Cash and cash equivalents

3,170

600

3,770

Trade receivables

1,156

210

1,366

Inventories

3,362

676

4,039

Property, plant and equipment

177

177

Right-of-use assets

3,815

1,873

5,687

Intangible assets

9,333

9,333

Other current and non-current assets

275

88

363

Trade payables

–418

–450

–868

Lease liabilities

–3,815

–1,873

–5,687

Net deferred tax assets/(liabilities)

–1,871

–1,871

Employee benefit liabilities

–378

–378

Other current and non-current liabilities

–596

–282

–878

Fair value of net assets

14,211

842

15,053

Goodwill

9,074

8,863

17,937

Purchase consideration

23,285

9,705

32,990

Cash acquired

–3,170

–600

–3,770

Deferred consideration

–630

–630

Contingent consideration

–2,385

–2,385

Net cash flow from current business combinations

17,730

8,476

26,206

Pro forma figures for acquisitions made in the first half of 2023

Since their inclusion in Galenica's scope of consolidation, the businesses acquired contributed net sales of CHF 6.3 million and an operating result (EBIT) of CHF 0.4 million to the Group's results. If these acquisitions had occurred on 1 January 2023, they would have contributed additional net sales of CHF 1.8 million without a material effect on EBIT.

Galenica utilise des cookies pour optimiser les fonctions du site et vous proposer la meilleure expérience possible. Utilisation des cookies et disclaimer